Case | HBS Case Collection | September 2013 (Revised August 2014)

Claritas Genomics

by Robert F. Higgins and Matthew Preble


Claritas Genomics was formed in January 2013 when BCH spun out its Genetics Diagnostic Lab into a fully commercial entity. Claritas offered over 100 genomic tests to detect a range of conditions, including autism and intellectual disabilities, and was developing new tests that provided clearer and more relevant information for physicians to use in treating patients. Claritas wanted to increase the speed at which genomic research discoveries occurred and translate this research into better diagnostic tests. To achieve this, it planned to collaborate with other children's hospitals through a research network it was developing. BCH was the company's majority owner, and Life Technologies (Life), a major manufacturer of sequencing equipment and services, was a minority owner. By the end of the year the CEO of Claritas Genomics, Dr. Patrice Milos, had to put Claritas in a position to grow and needed to have in place the software and IT platforms—the databases, search tools, and other programs—that would help the company reach scale.

Keywords: Boston Children's Hospital; genetic engineering; genetics; genetically modified; genetics diagnostics; information technology; Information Management; health care industry; healthcare IT; Healthcare Technology; healthcare ventures; Biotechnology Industry; Biomedical Research; Patrice Milos; genomics; genomic testing; Life Technologies; Health Care and Treatment; Information Technology; Information Management; Genetics; Biotechnology Industry; Information Technology Industry; Health Industry; Boston; Massachusetts; United States;


Higgins, Robert F., and Matthew Preble. "Claritas Genomics." Harvard Business School Case 814-032, September 2013. (Revised August 2014.)